BSI-510 / Biosion - LARVOL DELTA

BSI-510, a novel bispecific molecule combining an anti-Siglec-15 antibody with cytokine GM-CSF for enhanced antitumor efficacy (SITC 2023) - "Conclusions BSI-510 is a first-in-class anti-Siglec-15×GM-CSF bispecific fusion molecule combining simultaneous reversal of T cell inhibition and M2/M1 macrophage repolarization. BSI-510 demonstrates favorable biophysical and functional characteristics, supporting the initiation of development activities including manufacturing and IND-enabling studies."

Clinical • Oncology • Solid Tumor • CSF2 • SIGLEC15